Related Experiment Video

Updated: Mar 14, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

13.1K

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling

Hiu-Fung Yuen1, Ka-Kui Chan1, Angela Platt-Higgins2

  • 1Center for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.

Oncotarget
|October 8, 2016
PubMed

Insights

Ran knockdown reduces Met receptor expression, inhibiting cancer cell growth and migration. Co-overexpression of Met and Ran may indicate cancer progression and serve as a prognostic indicator.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cancer cells with activated oncogenic pathways, such as Met activation, depend on Ran for growth and survival.
  • Met receptor signaling is crucial for various cellular processes including adhesion, migration, and invasion.

Purpose of the Study:

  • To investigate the role of Ran in regulating Met receptor expression and its downstream signaling pathways in cancer cells.
  • To determine if Ran knockdown can sensitize cancer cells to targeted therapies like gefitinib.
  • To explore the clinical relevance of Ran and Met expression as prognostic markers in human breast cancer.

Main Methods:

  • Ran knockdown was performed in breast and lung cancer cell lines.
  • Met receptor expression, HGF expression, and downstream signaling pathways (Akt, ERK1/2) were analyzed.
  • Cell proliferation, adhesion, migration, and invasion assays were conducted.
  • Immunohistochemistry was used to assess Ran and Met levels in human breast cancer specimens.

Main Results:

  • Ran knockdown led to decreased Met receptor expression, suppressed HGF expression, and inhibited Met-mediated activation of the Akt pathway.
  • Ran knockdown reduced cancer cell adhesion, migration, and invasion.
  • In a gefitinib-resistant cell line model, Ran knockdown sensitized cells to gefitinib, reducing proliferation.
  • Met reduction by Ran knockdown occurred at the post-transcriptional level, potentially involving matrix metalloproteinases.
  • Positive association between Ran and Met levels was observed in human breast cancer specimens.

Conclusions:

  • Ran plays a critical role in regulating Met receptor expression and downstream signaling, impacting cancer cell behavior.
  • Targeting Ran may be a viable strategy to overcome resistance to therapies like gefitinib.
  • Co-overexpression of Met and Ran is associated with cancer progression and may serve as a combined prognostic indicator in breast cancer.
Keywords:
C-MetRan GTPbreast cancergefitiniblung cancer

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K
Experimental Metastasis Assay08:28

Experimental Metastasis Assay

Published on: August 24, 2010

21.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K